Tokyo, Mar 2, 2006 (JCN) - Takeda Pharmaceutical announced on March 2 that it received the exclusive right to use LG474, a substance discovered through its collaboration with Lexicon Genetics in the US. In July 2004, the two companies entered into a partnership under which Takeda can select and purchase promising targets for anti-hypertension medicine that were discovered in Lexicon’s Genome5000 program.
